CN115381885A - A Chinese medicinal composition for treating or relieving asthenopia or video syndrome - Google Patents
A Chinese medicinal composition for treating or relieving asthenopia or video syndrome Download PDFInfo
- Publication number
- CN115381885A CN115381885A CN202210954795.4A CN202210954795A CN115381885A CN 115381885 A CN115381885 A CN 115381885A CN 202210954795 A CN202210954795 A CN 202210954795A CN 115381885 A CN115381885 A CN 115381885A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- root
- video
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 46
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 100
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 24
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 24
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 23
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 23
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 23
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 22
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 22
- 241000202726 Bupleurum Species 0.000 claims abstract description 16
- 235000021028 berry Nutrition 0.000 claims abstract 2
- 240000006079 Schisandra chinensis Species 0.000 claims description 22
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 8
- 210000001508 eye Anatomy 0.000 abstract description 48
- 208000024891 symptom Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 4
- 230000002996 emotional effect Effects 0.000 abstract description 3
- 206010060891 General symptom Diseases 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 description 37
- 230000001886 ciliary effect Effects 0.000 description 32
- 230000004913 activation Effects 0.000 description 27
- 239000011575 calcium Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000033228 biological regulation Effects 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 15
- 241000700199 Cavia porcellus Species 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 208000005392 Spasm Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000003889 eye drop Substances 0.000 description 12
- 241000700198 Cavia Species 0.000 description 11
- 229940012356 eye drops Drugs 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000004308 accommodation Effects 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 208000001491 myopia Diseases 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 8
- 230000004379 myopia Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002146 bilateral effect Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 6
- 229960004484 carbachol Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 208000006550 Mydriasis Diseases 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 244000236521 Bupleurum rotundifolium Species 0.000 description 4
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002040 relaxant effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 208000028048 Accommodation disease Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000003164 Diplopia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- 208000001692 Esotropia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002911 mydriatic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000005554 pickling Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101000975407 Caenorhabditis elegans Inositol 1,4,5-trisphosphate receptor itr-1 Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101000975393 Drosophila melanogaster Inositol 1,4,5-trisphosphate receptor Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241001412225 Firmiana simplex Species 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 206010020015 Heterophoria Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 108091008585 IP3 receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002078 massotherapy Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome, which is prepared from the following components in parts by weight: 10 to 25 portions of white peony root, 10 to 25 portions of honey-fried licorice root, 5 to 15 portions of bupleurum and 2 to 10 portions of shizandra berry. The traditional Chinese medicine composition can relieve local symptoms of asthenopia patients, such as discomfort around eyes, tight feeling of eyes, soreness and distending pain, stabbing pain and the like, improve general symptoms and emotional abnormality caused by eye problems, and has short treatment action time, prolonged action time and accumulative effect.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome.
Background
Asthenopia is a common ophthalmic disease, and is mainly manifested by dry eyes, soreness and distension of eyes, blurred vision and even vision loss, which directly affect the work and life of people and aggravate under the conditions of emotional stress and poor sleep. Recorded in Tang dynasty Sun Simiao's book Qianjin Yao Fang: "the excessive reading and playing will hurt the eyes, which is called liver fatigue", and the common cause of this disease is overuse of eyes. Modern Chinese medicine considers that the occurrence of the disease is closely related to overuse of eyesight and mental strain, the disease is located in liver, heart and kidney, the pathogenesis of the disease is the exhaustion of the eyes, tendon is not relaxed, the essence and blood of liver and kidney are consumed, the essence and blood are insufficient, tendon is not nourished, and the regulation is disordered. From objective indexes, the visual system needs to keep clear focus on the external objects in a close distance and needs ciliary muscle contraction, lenticular protrusion and pupil contraction to realize, the visual system comprises the functional activities of cerebral cortex, the requirements of regulation stimulation must be met accurately and inerrably, and the eye muscles are guaranteed to have enough regulation reserve power and flexibility to maintain clear, comfortable and lasting vision of human eyes.
Research shows that the myopia prevalence rate can be obviously increased and the myopia degree can be deepened by continuously using the eyes at a short distance. For adults, especially white-collar people in offices nowadays, the long-term use of near-distance video screen terminals increases the tension of ciliary muscle to cause spasm, which is manifested as a series of visual fatigue symptoms mainly caused by visual disturbance, and investigation shows that 64-90% of computer workers can have the symptom. In the last two decades, scholars at home and abroad find that the incidence rate of the asthenopia is positively correlated with the use of the video terminal, and the incidence rate is gradually increased year by year. The visual fatigue not only affects the work and affects the mood, but also seriously affects the life and the working quality of patients, and even induces the occurrence of psychological diseases such as depression and anxiety, and the intervention and treatment are urgent. At present, the market prospect of the visual fatigue treatment is huge, but the treatment means is single, and the variety of health care and auxiliary products is various, so that effective and formal treatment means is very important and urgently needed.
A video terminal (VDT) operates a VDT syndrome, i.e., when watching a computer screen or operating a computer, complicated vision and eye problems are caused due to excessive application of near vision for a long time, which is generally referred to as VDT asthenopia syndrome by experts. VDT workers are characterized by vision that moves back and forth between the document, keyboard, and screen for long periods of time, thus requiring relatively frequent eye activity. Animal experiments of foreign scholars Katsuyama and the like show that when the eyeball movement of an experimental object exceeds a certain load, if timely and sufficient rest is not obtained, the extraocular muscles are fatigued, particularly ciliary muscles, the adjusting capability of human eyeballs is reduced, and the asthenopia is caused. Experiments by the scholars of Yoshioka and the like show that visual fatigue is obviously related to the exposure time of a computer screen, the sleep quality and the like, and the exposure of the computer screen is obviously linear if the exposure time is more than 6 hours per day, and VDT is the main reason of the visual fatigue at present.
The main treatment means at present are: and (3) western medicine treatment: (1) correcting ametropia. (2) a surgical method. Mainly comprises the operation modes of corneal surgery, external rectus muscle posterior migration, internal rectus muscle excision and the like. And (3) chemotherapy. (4) The eye external muscle training, psychological consultation and the adoption of methods such as a polarizing filter can all play a role in relieving visual fatigue. The traditional Chinese medicine treatment comprises the following steps: (1) the oral administration of Chinese medicinal materials. (2) external treatment of traditional Chinese medicine: eye drop preparation: improving visual function, relieving local spasm, dilating blood vessel wall of eye, and promoting microcirculation of eye. (2) Chinese medicine fumigation. (3) Chinese medicine hot pickling bag: the Chinese medicinal materials are cured by hot pickling and packaging in combination with acupoint massage. (4) acupuncture and massage therapy.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the invention provides a traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome, which is prepared from the following components in parts by weight: 10 to 25 portions of white peony root, 10 to 25 portions of honey-fried licorice root, 5 to 15 portions of bupleurum and 2 to 10 portions of schisandra fruit.
The traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight: 10 to 20 portions of white peony root, 10 to 20 portions of honey-fried licorice root, 6 to 12 portions of bupleurum and 3 to 9 portions of schisandra fruit.
The traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight: 20 parts of white peony root, 20 parts of honey-fried licorice root, 10 parts of bupleurum root and 6 parts of schisandra fruit.
The traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight: 20 parts of white peony root, 18 parts of honey-fried licorice root, 12 parts of bupleurum root and 6 parts of schisandra fruit.
The traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight: 12 parts of white peony root, 12 parts of prepared liquorice root, 9 parts of bupleurum and 3 parts of schisandra chinensis.
The traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight: 15 parts of white peony root, 15 parts of honey-fried licorice root, 12 parts of bupleurum and 9 parts of schisandra chinensis.
The traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight: 10 parts of white peony root, 10 parts of honey-fried licorice root, 6 parts of bupleurum root and 6 parts of schisandra fruit.
The second aspect of the invention provides an application of the traditional Chinese medicine composition in preparing a medicine for treating or relieving visual fatigue or video syndrome.
Due to the adoption of the technical scheme, the invention has the following advantages and beneficial effects:
the traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome provided by the invention can relieve local symptoms of asthenopia patients, such as discomfort around eyes, tight feeling of eyes, soreness and distending pain, stabbing pain and the like, improve general symptoms and emotional abnormality caused by eye problems, has short treatment action time, and has cumulative effect after being prolonged along with time.
The traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome provided by the invention can improve the activation region of the central cortex of brain vision, thereby improving the regulation of eye ciliary muscle and relieving asthenopia symptoms, and can treat eye regulation spasm and relax the ciliary muscle.
Drawings
FIG. 1 is a schematic view of a voxel range image of each bolus activation in the brain activation region when the myopia is modulated at-3.00D before zheng certain treatment.
FIG. 2 is a schematic view of a voxel range image of each bolus activation in the brain activation region when the near-3.00D accommodation occurs after a certain treatment.
Fig. 3 is a schematic view of a voxel range image of each mass activation in the brain activation region (the left eye is the dominant eye) when normal human myopia is adjusted at-3.00D.
Figure 4 is a schematic representation of the model group guinea pig under-ciliary-myoscopic observation (× 400).
Figure 5 is a schematic under-lens observation of ciliary muscle of guinea pig at high concentration of traditional Chinese medicine (x 400).
Detailed Description
In order to more clearly illustrate the invention, the invention is further described below in connection with preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
Example 1
A traditional Chinese medicine composition is prepared from the following components in parts by weight:
20g of white peony root, 20g of honey-fried licorice root, 10g of radix bupleuri and 6g of Chinese magnoliavine fruit.
The preparation method of the Chinese medicinal composition decoction comprises the following steps:
firstly, soaking the medicines in 500mL of water for 30-60 minutes, wherein the water consumption is most suitable higher than the surface of the medicines.
The second step, the times of decocting the Chinese medicine generally requires that the Chinese medicine is decocted twice, and the water consumption when decocting the Chinese medicine again should be: the water addition amount of the second decoction is one third to two thirds of that of the first decoction.
Thirdly, the duration and duration of the decoction: boiling with strong fire, boiling with slow fire for 30 minutes after the water is boiled, and stopping the fire.
Methods of use and effective dosages of the medicament: orally administered 2 times a day at 100ML each time.
The traditional Chinese medicine composition of the invention comprises the following sources and addition and subtraction components: radix Paeoniae alba (20 g), radix Glycyrrhizae Preparata (20 g), bupleuri radix (10 g), and fructus Schisandrae (6 g). The prescription is derived from Shang Han Lun of Zhang Zhongjing, and the medicine comprises the following components: radix Paeoniae alba, and radix Glycyrrhizae Preparata (12 g). The prescription has the following effects: nourish liver and yin, relieve spasm and alleviate pain. The original recipe is mainly indicated for the syndromes of impaired body fluid, deficiency of yin and blood, and loss of moistening of tendons and vessels.
In the formula, the peony is sour and cold, and has the effects of nourishing blood, astringing yin, softening liver and relieving pain; licorice root, radix Glycyrrhizae is sweet and warm in nature, and has the effects of invigorating spleen, replenishing qi, and relieving spasm and pain. The compatibility of the two medicines can regulate the liver and spleen, soften the tendons and relieve the pain. The components of the peony and the liquorice have the functions of tranquilizing, easing pain, relieving fever, resisting inflammation and relaxing smooth muscle, and the functions can be obviously enhanced after the two medicines are combined. Bupleuri radix is slightly cold in nature and bitter in taste, enters liver channel, gallbladder channel and lung channel, and has effects of dispelling pathogenic wind, relieving fever, dispersing stagnated liver qi, relieving qi stagnation, and invigorating yang; the schisandra chinensis has the effects of astringing lung, nourishing kidney, promoting fluid production, soothing nerves, nourishing yin and aiding sleep; radix Paeoniae and Glycyrrhrizae radix are combined with bupleuri radix to soothe liver and relieve depression, nourish yin and tranquilize mind, and the combined formula nourishes liver body to help liver, and is used for body conditioning.
Example 2
The clinical research on the treatment of the eye spasm by the traditional Chinese medicine composition of the invention comprises the following steps:
the clinical experiment adopts a random, contrast and double-blind research method. According to the corresponding inclusion and exclusion criteria, 60 patients (120 eyes) were selected from the affiliated eosin hospital of Shanghai medical university from 9 months 2017 to 2 months 2019 for ophthalmic visits and confirmed as "eye accommodation spasm". All patients were divided into 2 groups using the random number table method, treatment groups: conventional western medicine mode + treatment with the traditional Chinese medicine composition was given, and the control group: plain western plus placebo treatment was given. Conventional western medicine methods: including correcting and wearing proper myopia or hypermetropia glasses; eye drops are given every night after the Xinliuding is given; the artificial tear eye drops are taken three times a day. The traditional Chinese medicine composition of the invention is as follows: radix Paeoniae alba (20 g), radix Glycyrrhizae Preparata (20 g), bupleuri radix (10 g), and fructus Schisandrae (6 g) by decocting in the morning and evening. The placebo consists of: 5 percent of the Chinese medicinal composition granules are added with 95 percent of maltodextrin to prepare the granules. The treatment period was 4 weeks.
The observation index and the method comprise: (1) subjective symptom scoring criteria; (2) Ocular routine exams (naked eye vision, corrected vision, intraocular pressure, eye position, eye movement, fusion, concentration, dominant eye, and anterior and posterior segment of the eye exams); (3) The main observation indicators (amplitude of regulation, regulation response, regulation sensitivity and negative phase regulation).
The traditional Chinese medicine composition provided by the invention is combined with a conventional western medicine treatment mode to improve subjective symptom feeling of a patient, increase negative relative regulation and relax eye ciliary muscle, and has the advantages of being superior to the effect of the conventional western medicine treatment mode and high in safety. Can relieve the physical and mental discomfort of the patients and improve the life quality.
Table 1: two groups of data after treatment are compared and analyzed-t test result
Table 2: comparative analysis of two sets of post-treatment data-non-parametric test results
Note: * Denotes that P <0.01 has significant statistical significance, # denotes that P <0.05 has statistical significance, and # denotes that P >0.05 has no statistical significance.
Two groups of data after treatment are compared and analyzed-t test results show that: in both groups (i.e., groups) there was a statistical difference between the two indices of anterior chamber depth and amplitude of accommodation. Compared with the control group, the treatment group of the traditional Chinese medicine composition has different anterior chamber depth and adjustment amplitude compared with the control group, and the capacity of the treatment group for increasing the anterior chamber depth and improving the adjustment amplitude of a patient is better than that of the control group. While for positive relative regulation, there was no difference in the intra-group comparisons. Two sets of post-treatment data were compared-results of nonparametric tests are shown: compared in groups, the three indexes of subjective symptom scoring, accommodation sensitivity and negative relative accommodation are statistically different, and the treatment group can improve subjective symptom feeling of patients, improve eye accommodation sensitivity of the patients, increase eye negative relative accommodation capacity of the patients, and has the effects of relaxing and adjusting, relaxing ciliary muscle and relieving uncomfortable fatigue symptoms.
Example 3
The traditional Chinese medicine composition provided by the invention has the effect of intervening guinea pigs in eye spasm regulation models
Establishing a puffer eye accommodation spasm model: before the experiment, all guinea pigs were examined and the subjects with significant deviation of the refractive power from the population were excluded to avoid the error caused by high myopia in individual guinea pigs. 18 male guinea pigs with flowers are screened out, and models are established for both eyes. After guinea pigs were adaptively fed for 1-3 days, guinea pigs were randomly divided into two groups, one group was modeled with carbachol eye drops at a concentration of 2ml. The AB two groups are respectively divided into three groups randomly according to a random number table method, wherein the drug-dropping times of the A1 group and the B1 group are respectively 1 time/day, the drug-dropping times of the A2 group and the B2 group are respectively 2 times/day, and the drug-dropping times of the A3 group and the B3 group are respectively 3 times/day.
Before establishing the model, the guinea pig is examined in the dark room without mydriasis, and the refractive state is recorded. And then dripping the 0.5% compound topiramide eye drops for 3 times at an interval of 5min every time, finishing dripping the medicine for 30min at the last time, performing image detection in a dark room, and recording data. During the examination, the guinea pig was conscious, the assisting person pacified the guinea pig to calm it down, the examined person performed an examination refraction on the horizontal meridian at a position of 0.5m from the guinea pig, the gradient of the increase in the lens was 0.25D, and the astigmatism was converted with a half-equivalent sphere. The time of each neutralization action does not exceed 30s, and after three times of each eye, the data are averaged and recorded. After mydriasis examination, the model is made every other day in the afternoon. The eye was instilled daily with carbachol eye drops over the same period of time. Examination in the dark room without mydriasis was performed 1, 3, 7, 14, 21 days before dosing and data was recorded.
The successful establishment of the model is as follows: a fixed examination distance of 0.5m induces an adjustment force of 2.00D; and (3) examining the optometry under the non-mydriatic pupil after the molding, examining the optometry under the mydriatic pupil before the molding, and the multiple adjustment power (unit D), wherein when the index is more than or equal to 0.50D, the spasm adjustment molding is judged to be successful. All the optometry operations are operated by the same experimenter to ensure the consistency of the model.
The traditional Chinese medicine composition provided by the invention can be used for treating Ca in ciliary muscle tissue of a guinea pig spasm regulation model 2+ Modulation of expression. Intracellular Ca 2+ The increase in concentration is the major mechanism of smooth muscle contraction, while activation of IP3R, RYR is intracellular Ca 2+ The important way of increasing the concentration. Calcium kit detection method (microplate method) technology is used for detecting Ca in ciliary muscle tissues of guinea pig blank control group, spasm regulation model group and traditional Chinese medicine gavage group with different concentrations 2+ The concentration of (2). Ciliary muscle homogenizing method: guinea pig Co2 was euthanized, the eyeball was removed, ciliary muscle tissue was completely removed under a microscope with toothless tweezers, water was blotted with absorbent paper, and the tissue was stored in a refrigerator at-80 ℃. Taking out ciliary muscle tissue specimen, thawing at room temperature, using deionized water as a homogenizing medium, preparing 10% uniform single cell liquid under ice bath with power of 800W and 10000 rpm. Homogenizing for 5s, and standing for 30min. Centrifuging for 15min on a high-speed centrifuge with low temperature of 15000rpm on ice, and sucking supernatant liquid to store in a refrigerator at-20 ℃ for later use.
Experimental grouping: 60 flower guinea pigs were used for both eyes. The groups were randomized into three groups: blank group 12 (sterile injection for intragastric administration); model group 12 (sterile injection gavage); 36 traditional Chinese medicines are: 12 high-concentration samples; medium concentration is 12; the low concentration is 12. Animal drug calculation, equivalent dose of guinea pig (equivalent to adult dose of 60 Kg) was calculated from "equivalent dose ratio table in terms of body surface area between human and animal": 2.7mg/g. Soaking the raw materials, decocting (boiling in water for 1 hr, filtering, boiling the residue in water for 1 hr, mixing the two decoctions, filtering, concentrating at 90 deg.C to obtain a decoction: the high dose group was 1.08g/ml, the medium dose was 0.54g/ml, and the low dose group was 0.27g/ml. Blank group and model group were examined and tested under non-mydriasis on 7 days, 14 days, 21 days and 28 days after model group establishment, 3 guinea pigs were sacrificed, and Chinese medicinal materials with different concentrations were examined and tested under non-mydriasis on 7 days, 14 days, 21 days and 28 days after gastric lavage, and 3 guinea pigs were sacrificed. In fact, five groups of dead guinea pigs are obtained at the same time point, 1 eyeball is fixed and paraffin is sliced, and the rest 5 eyeballs are stored in a refrigerator at the temperature of-80 ℃ for later experimental detection.
The traditional Chinese medicine composition disclosed by the invention can be used for reducing Ca in ciliary muscle tissue of a spastic guinea pig model 2+ The expression data of (A) are shown in tables 3 to 5:
TABLE 3 Ca in the supernatant of the homogenate of ciliary muscle tissue at different time points for each group 2+ Concentration of (a) × +/-s (mmol/g)
| Blank control group | Model set | Low concentration group | Middle concentration group | High concentration group | |
| 7 days | 0.46±0.0007×10 -3 | 0.94±0.54×10 -3 | 0.78±1.22×10 -3 | 0.71±0.0007×10 -3 | 0.67±0.42×10 -3 |
| 14 days | 0.52±0.0007×10 -3 | 1.11±0.0007×10 -3 | 1.09±0.6×10 -3 | 1.03±1.75×10 -3 | 0.96±2.05×10 -3 |
| 21 days | 0.52±0.58×10 -3 | 1.23±2×10 -3 | 1.21±0.66×10 -3 | 1.16±0.6×10 -3 | 1.6±2.73×10 -3 |
| 28 days | 0.54±0.9×10 -3 | 1.5±0.79×10 -3 | 1.32±1.63×10 -3 | 1.29±0.0007×10 -3 | 1.27±1.57×10 -3 |
TABLE 4 Ca in ciliary muscle tissue at different time points within each group 2+ Expression level statistics F/P value scale
TABLE 5 Ca between groups at 7 days 2+ Statistical P-value scale for expression levels
Note: * Denotes that P <0.01 has significant statistical significance, # denotes that P <0.05 has statistical significance, and # denotes that P >0.05 has no statistical significance.
And (4) conclusion: as can be seen in tables 3-4, blank group Ca 2+ The concentration of Ca is obviously lower than that of Ca in the other 4 groups, the model group and the Chinese medicine groups at different time points 2+ The concentrations are different, 28 days>21 days>14 days>7 days, and the content at each time point was higher than that of the blank group. The carbachol eye drops can make Ca in ciliary muscle tissue 2+ The content increases and grows with the accumulation of the application time, which indicates the success of molding. As can be seen in Table 5, the comparison between each group at 7 days was different (P)<0.01). Further performing multiple comparisons, the comparison between the model group and the Chinese medicinal herbs with low, medium and high concentrations is different (P)<0.05 Indicate Ca in ciliary muscle tissue of guinea pig on day 7 after intragastric administration 2+ The concentration content is lower than that of a model group, namely the traditional Chinese medicine can resist the Ca induced by the carbachol eye drops 2+ The concentration is increased. The two groups at low and high concentrations also have difference (P)<0.05 High concentration is more capable of preventing Ca than low concentration) 2+ The concentration of (3) is increased. Further observing the influence of the traditional Chinese medicine on the calcium concentration in tissues, finding that the low, medium and high concentration traditional Chinese medicines can resist the Ca induced by the carbachol eye drops in 7 days 2+ The internal flow is realized, and the medium and high concentration is more advantageous. It can be seen that the traditional Chinese medicine can induce Ca in ciliary muscle tissue by carbachol eye drops 2+ The concentration rise has certain inhibiting effect, and the effect of the high-concentration traditional Chinese medicine is more obvious. Intracellular Ca 2+ The increase in concentration is the primary mechanism of smooth muscle contraction, relaxing the tense ciliary muscle, and relaxation regulation is critical for relief of asthenopia.
Example 4
The traditional Chinese medicine composition is used for treating 1 case of acute common esotropia caused by ciliary muscle adjustment, magnetic resonance examination after treatment shows that the activation range and the activation strength of a brain area are increased, the activation mode is close to that of a normal person, and the clinical symptoms are improved. With the popularization of electronic products, continuous close work can cause the tension of the rectus muscles in eyes to increase and the adjustment and convergence dysfunction, thereby causing the visual dysfunction of both eyes. If the binocular fusion range is below normal, acute commonality esotropia (AACE) is easily induced, resulting in diplopia. The etiology may be related to impaired fusion function, myopia, accommodation, overuse of the eyes, heterophoria, physical condition or mental factors. The patient is treated after 1 year of double-eye distant double-vision review: (1) The topiramate eye drops are 3 drops before sleep every night at an interval of 5min; (2) For the treatment of the traditional Chinese medicine, the traditional Chinese medicine composition (10 g of Chinese thorowax root, 20g of honey-fried licorice root, 20g of white paeony root and 6g of Chinese magnoliavine fruit) is administered, 14 doses of herbal medicines are decocted per day, and the oral administration is carried out for 2 times in the morning and at the evening; patients who follow up after 3d had better sleep than before, and the double vision symptom was better in the morning. After the medicine is taken for 1 month, the medicine is obviously improved and still repeated, and after the medicine is taken for one month, the compound vision and the fatigue are only occasionally caused, so that the improvement of the fusion function is obvious in the long-term and the normal life is not influenced.
FIG. 1 is a schematic view of a voxel range image of each bolus activation in the brain activation region when the myopia is modulated at-3.00D before zheng certain treatment. Mog.r right occipital gyrus (white arrow); cal.r right rectangular cleft and its surrounding cortex (white arrow), cun.r right cuneiform (white arrow), pcun.l/R bilateral anterior cuneiform (white arrow). Functional magnetic resonance imaging (fMRI) is performed in the department of radiology, acquired task state (observing an 'E' visual target under the condition of adjusting and stimulating dominant eye-3.00D) image data are preprocessed and subjected to first-order analysis by spm12 software, and a result is shown after the horizontal correction of a False Discovery Rate (FDR) lump: bilateral anterior cuneiform, right occipital inferior, right cuneiform, right cleft and its peripheral cortex activation.
FIG. 2 is a schematic view of a voxel range image of each bolus activation in the brain activation region when the near-3.00D accommodation occurs after a certain treatment. Cerebellum 8 region right/left cerebellum 8 (white arrow) of cerebellum _8 _r/L; mog.r right occipital gyrus (white arrow); cal.r right rectangular fissure and its surrounding cortex (white arrow); r right prefrontal gyrus (white arrow); ifgoperc. R right island cap section is returned (white arrow); top lower edge corner of ipl.l (white arrow); pcl.l left lateral leaflet (white arrow).
As compared to normal brain region activation maps, the extent and intensity of brain region activation in patients is reduced, and its mechanism may be related to neurological feedback inhibition that regulates collective functions. The brain activating areas after treatment of the patient in this example are bilateral cerebellum 8 areas, right rectangular fissure and its peripheral cortex, right occipital gyrus, right islet periparietal gyrus, apical inferior border horn gyrus, left central paralobule, and right frontal gyrus. Compared with the treatment before (figure 1), the activation range and the activation intensity of the brain area are increased, and the activation mode is close to that of a normal person. The traditional Chinese medicine can improve the eye regulation function, the regulation factors play a key role in the disease attack process, and the comparison before and after treatment shows that the activation area of the brain is obviously increased after the treatment, which is the reason for improving the clinical symptoms. The traditional Chinese medicine composition can be used as a medicine for treating or relieving visual fatigue or video syndrome.
Fig. 3 is a schematic view of a voxel range image of each mass activation in the brain activation region (the left eye is the dominant eye) when normal human myopia is adjusted at-3.00D. Cal.l left rectangular fissure and its surrounding cortex (white arrow); mog.l left occipital gyrus (white arrow); tha.l/R bilateral thalamus (white arrows); cal.r right rectangular cleft and its surrounding cortex (white arrow).
The left eye is the dominant eye, and the degree of sphere is shown in the diagram of brain activation under approximately the same normal human-3.00D accommodation stimulus: bilateral rhabdoid fissure and its peripheral cortex, left occipital gyrus, and bilateral thalamus activation, which are used as reference for control after treatment.
Example 5
fMRI (functional nuclear magnetic resonance examination) is applied to the brain functional characteristic analysis of the population with the adjustable asthenopia and the central regulation mechanism research of the traditional Chinese medicine intervention.
The patients with asthenopia who were visited by the ophthalmology clinic of the eosin hospital affiliated to the university of medicine in the sea above, doctors, scholars and researchers in hospitals served as the subjects for recruitment and screening. All the specific steps involved in the study procedure (including questionnaire filling, slit lamps, phoropter, autorefractor, IOLmaster500, co-optometric examination) were performed in the ophthalmology outpatient clinic in the purdonary hospital of eosin. The study was screened for inclusion in patients starting at 2018, 11, and all trials ended up with the follow-up by 1 month at 2020. 127 subjects were screened and a final total of 80 were in compliance with the diagnostic criteria. 80 patients were randomly assigned to the traditional Chinese medicine treatment group (43) and the placebo control group (37) at a ratio of 1. Subjects were prohibited from taking antihistamines, anticholinergics, thyroid hormones, antidepressants, antithyroid drugs and ginkgo biloba extracts during the study, which might affect ocular surface condition for systemic use and thus are prohibited.
Drug configuration and experimental grouping: the traditional Chinese medicine treatment group and the placebo control group receive a basic treatment scheme (refraction correction, 3 times per night by tropicamide eye drops), and meanwhile, the traditional Chinese medicine treatment group gives the traditional Chinese medicine composition granules (12 g of radix bupleuri, 20g of white peony root, 18g of honey-fried licorice root and 6g of vinegar schisandra chinensis), 1 dose is taken every day, morning and evening, and the treatment course lasts for 8 weeks; placebo control group was administered placebo (with the same color, texture and packaging as the Chinese medicinal composition granules of the present invention) 1 dose per day, orally in the morning and evening, for a treatment period of 8 weeks.
The partial action mechanism of the traditional Chinese medicine composition for treating the patient with the eye spasm is probably to reduce Ca in ciliary muscle tissues by inhibiting the expression of IP3 receptors in ciliary muscle tissues and influencing the activation of calcium release channels in CICR 2+ Is realized by the expression of (1).
Based on the feasibility of exploring the traditional Chinese medicine composition for treating the eye spasm based on the smooth muscle contraction mechanism, experiments show that the traditional Chinese medicine composition can relax the guinea pig ciliary muscle (see figure 4 and figure 5) and can reduce Ca in the ciliary muscle tissue of a spasm guinea pig model 2+ Expression of (2). Fig. 4 is a schematic diagram of a model group of guinea pigs observed under ciliary muscle light microscopy (× 400). Fig. 5 is a schematic under-lens observation of ciliary muscle of guinea pig with high concentration of traditional Chinese medicine (x 400). It can be seen from the figure that in HE staining of paraffin sections of the ciliary muscle, staining of ciliary muscle in accommodation spasm model was darker and more closely arranged than in normal guinea pig ciliary muscle. The traditional Chinese medicine composition can relieve the spastic state of ciliary muscle, improve the form of ciliary muscle and help to relieve visual fatigue, and can be used for treating or relieving visual fatigueThe use of drugs for labor or video syndromes.
Example 6
A traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight:
20g of white peony root, 20g of honey-fried licorice root, 10g of Chinese thorowax root and 6g of Chinese magnoliavine fruit.
The preparation method of the traditional Chinese medicine composition granules comprises the following steps: soaking the medicines, namely soaking all the medicinal materials in 500mL of water for 30 to 60 minutes, wherein the water consumption is most suitable higher than the surface of the medicines. The frequency of decocting the Chinese medicinal herbs generally requires that the Chinese medicinal herbs are decocted twice, and the water consumption for decocting the Chinese medicinal herbs again is as follows: the water adding amount of the second decoction is one third to two thirds of that of the first decoction. The decoction duration and time are as follows: boiling with strong fire, boiling with slow fire for 30 minutes after the water is boiled, and stopping the fire. Methods of use and effective dosages of the medicament: orally administered 2 times a day at 100ML each time.
Example 7
A traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight:
20g of white peony root, 20g of honey-fried licorice root, 10g of Chinese thorowax root and 6g of Chinese magnoliavine fruit.
The preparation method of the water-honeyed pill of the traditional Chinese medicine composition comprises the following steps: the medicines are ground into fine powder, sieved by a 100-mesh sieve, evenly activated, made into pills by water, like phoenix tree seeds, dried in the sun and stored in bottles for later use. The use method comprises the following steps: the medicine is taken orally, 3g is taken each time, twice a day and taken together with warm boiled water.
Example 8
A traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight:
12g of white peony root, 12g of honey-fried licorice root, 9g of bupleurum and 3g of schisandra chinensis.
The preparation method of the traditional Chinese medicine composition tablet comprises the following steps: taking the raw materials in proportion, adding 50% ethanol, reflux extracting twice, the first time for 40min. Filtering for 20min, mixing extractive solutions, concentrating, adding tablet adjuvants, and making into tablet.
Example 9
A traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is prepared from the following components in parts by weight:
15g of white peony root, 15g of honey-fried licorice root, 12g of radix bupleuri and 9g of Chinese magnoliavine fruit.
The preparation method of the Chinese medicinal composition capsule comprises the following steps: decocting the above materials in water twice for 40min. Filtering for 20min, mixing decoctions, concentrating, adding capsule adjuvants, and making into capsule.
Example 10
A traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome is prepared from the following components in parts by weight:
10g of white peony root, 10g of honey-fried licorice root, 6g of Chinese thorowax root and 6g of Chinese magnoliavine fruit.
The preparation method of the traditional Chinese medicine composition granules comprises the following steps: decocting the above materials in water twice for 40min. Filtering for 20min, mixing decoctions, concentrating, adding dextrin, drying, and making into granule. 1g of granules is equivalent to 5g of raw material medicines, 5g of the raw material medicines are taken each time, and the granules are taken twice a day by being mixed with warm water.
Although the present invention has been described with reference to a preferred embodiment, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (8)
1. A traditional Chinese medicine composition for treating or relieving visual fatigue or video syndrome is characterized by being prepared from the following components in parts by weight: 10 to 25 portions of white peony root, 10 to 25 portions of honey-fried licorice root, 5 to 15 portions of bupleurum and 2 to 10 portions of shizandra berry.
2. The traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome according to claim 1, which is prepared from the following components in parts by weight: 10 to 20 portions of white peony root, 10 to 20 portions of honey-fried licorice root, 6 to 12 portions of bupleurum and 3 to 9 portions of schisandra fruit.
3. The traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome according to claim 1 or 2, which is prepared from the following components in parts by weight: 20 parts of white peony root, 20 parts of honey-fried licorice root, 10 parts of bupleurum root and 6 parts of schisandra fruit.
4. The traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome according to claim 1 or 2, which is prepared from the following components in parts by weight: 20 parts of white peony root, 18 parts of honey-fried licorice root, 12 parts of bupleurum root and 6 parts of schisandra fruit.
5. The traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome according to claim 1 or 2, which is prepared from the following components in parts by weight: 12 parts of white peony root, 12 parts of honey-fried licorice root, 9 parts of bupleurum root and 3 parts of schisandra fruit.
6. The traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome according to claim 1 or 2, which is prepared from the following components in parts by weight: 15 parts of white peony root, 15 parts of honey-fried licorice root, 12 parts of bupleurum root and 9 parts of schisandra fruit.
7. The traditional Chinese medicine composition for treating or relieving asthenopia or video syndrome according to claim 1 or 2, which is prepared from the following components in parts by weight: 10 parts of white peony root, 10 parts of honey-fried licorice root, 6 parts of bupleurum root and 6 parts of schisandra fruit.
8. Use of a Chinese medicinal composition as claimed in any one of claims 1 to 7 in the preparation of a medicament for the treatment or alleviation of asthenopia or video syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210954795.4A CN115381885A (en) | 2022-08-10 | 2022-08-10 | A Chinese medicinal composition for treating or relieving asthenopia or video syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210954795.4A CN115381885A (en) | 2022-08-10 | 2022-08-10 | A Chinese medicinal composition for treating or relieving asthenopia or video syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115381885A true CN115381885A (en) | 2022-11-25 |
Family
ID=84117892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210954795.4A Pending CN115381885A (en) | 2022-08-10 | 2022-08-10 | A Chinese medicinal composition for treating or relieving asthenopia or video syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115381885A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108114061A (en) * | 2016-11-30 | 2018-06-05 | 财团法人工业技术研究院 | Use of Chinese herbal medicine extract and pharmaceutical composition containing the same and steroid |
-
2022
- 2022-08-10 CN CN202210954795.4A patent/CN115381885A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108114061A (en) * | 2016-11-30 | 2018-06-05 | 财团法人工业技术研究院 | Use of Chinese herbal medicine extract and pharmaceutical composition containing the same and steroid |
Non-Patent Citations (1)
| Title |
|---|
| 吕小利: "fMRI评价加味芍药甘草汤改善急性共同性内斜视1例", 中国中医眼科杂志 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008596B (en) | Chinese medicine eye compressing bag for treating myopic eye | |
| CN102188604A (en) | Medicament for treating myopia and presbyopia | |
| CN101279008A (en) | Chinese medicine pad pasting for preventing and controlling myopic eye, eyestrain symptoms and eyebase ischemia | |
| CN111035748A (en) | Traditional Chinese medicine composition for improving myopia, external application preparation for improving myopia and eye patch for improving myopia | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| CN101810824B (en) | Chinese medicament for curing post-stroke hand-shoulder syndrome | |
| CN105168590A (en) | Traditional Chinese medicine for treating xerophthalmia | |
| CN104524464A (en) | Traditional Chinese medicine preparation for treating hyperactivity and preparation method of traditional Chinese medicine preparation | |
| CN112402554B (en) | Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof | |
| CN112121104B (en) | Traditional Chinese medicine composition for relieving asthenopia and preventing and treating myopia | |
| CN104524188A (en) | Medicament for treating vascular dementia and preparation method of medicament | |
| CN115381885A (en) | A Chinese medicinal composition for treating or relieving asthenopia or video syndrome | |
| CN107029037A (en) | It is a kind of to improve the eyesight-improving health care function patch of eyes based on nitric oxide principle | |
| CN104800663A (en) | Traditional Chinese medicinal liquor for treating hyperostosis and preparation method of traditional Chinese medicinal liquor | |
| CN108498615A (en) | A kind of Chinese herb medicine eye health-care patch and preparation method thereof improving eyes based on nitric oxide principle | |
| CN102836316A (en) | Chinese medicine preparation for treating amblyopia | |
| CN110269895A (en) | A kind of visual rehabilitation Chinese medicine composition containing fresh Chinese medicine and preparation method thereof, preparation | |
| CN102631586B (en) | Medicinal moxibustion preparation for treating myopia and amblyopia | |
| Han et al. | Clinical observation on the prevention and treatment of juvenile mild myopia with traditional Chinese medicine comprehensive therapy | |
| CN103751358B (en) | A kind of Chinese medicine composition for rescuing ametropia ophthalmic | |
| CN102755549A (en) | Drug for curing cataract and preparation method thereof | |
| CN107617081A (en) | The Chinese medicine composition and its preparation and preparation method of a kind of hair growth | |
| CN118001317A (en) | Externally applied traditional Chinese medicine and eye patch for treating fundus macular degeneration and preparation method thereof | |
| CN104840774A (en) | Traditional Chinese medicine for treating liver and kidney yin deficiency and liver yang hyperactivity type hypertension | |
| CN104524036A (en) | Traditional Chinese medicine preparation for treating optic neuritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221125 |
|
| RJ01 | Rejection of invention patent application after publication |